As Insurers Cut Brokers’ Commissions, Consumers May Have One Less Resource
Some major insurance companies are opting not to pay commissions for plans sold in the Affordable Care Act’s marketplaces, while others are cutting their commissions. Will this make enrollment season more difficult for consumers?
Pricey New Treatment Roils Issues Of How To Treat Prostate Cancer
High-intensity focused ultrasound, often not covered by insurance, leads to discussions about which patients benefit in the real world.
The Ads Say ‘Get Your Flu Shot Today,’ But It May Be Wiser To Wait
The flu vaccine is available for longer windows of time. Experts say to weigh convenience and science in deciding when to roll up your sleeve.
It’s Not Just For Kids: Medicare EpiPen Spending Up 1,100 Percent
The number of prescriptions for Medicare beneficiaries is on the rise, too.
Cardiac Rehab Improves Health, But Cost And Access Issues Complicate Success
Research shows exercise-based cardiac rehab programs help heart patients heal faster and live longer. But fewer than a third take part. Time and cost are the main barriers, doctors and patients say.
Mylan’s Generic EpiPen — A Price Break Or Marketing Maneuver?
As news that Mylan will make available a generic version of its own brand-name product, KHN answers key questions about how this development could affect consumers.
Medicare’s Drug-Pricing Experiment Stirs Opposition
A proposal to change the way Medicare pays for some drugs has set off intense reaction and lobbying — all tied to a common theme: How far should the government go in setting prices for prescription drugs?
EPA Chief McCarthy: Public Health Is ‘What We Do’
Gina McCarthy met with Kaiser Health News to answer a range of questions, including how the agency is involved in efforts to combat Zika and the ongoing water crisis in Flint, Michigan.